Faculty Collaboration Database

Update on peripartum cardiomyopathy. Obstet Gynecol Clin North Am 2010 Jun;37(2):283-303

Date

08/06/2010

Pubmed ID

20685554

DOI

10.1016/j.ogc.2010.02.003

Scopus ID

2-s2.0-79952015701 (requires institutional sign-in at Scopus site)   16 Citations

Abstract

Although multiple mechanisms have been postulated, peripartum cardiomyopathy (PPCM) continues to be a cardiomyopathy of unknown cause. Multiple risk factors exist and the clinical presentation does not allow differentiation among potential causes. Although specific diagnostic criteria exist, PPCM remains a diagnosis of exclusion. Treatment modalities are dictated by the clinical state of the patient, and prognosis is dependent on recovery of function. Randomized controlled trials of novel therapies, such as bromocriptine, are needed to establish better treatment regimens to decrease morbidity and mortality. The creation of an international registry will be an important step to better define and treat PPCM. This article discusses the pathogenesis, risk factors, diagnosis, management, and prognosis of this condition.

Author List

Cruz MO, Briller J, Hibbard JU

Authors

Meredith Cruz MD Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin
Judith Hibbard Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Animals
Apoptosis
Autoimmune Diseases
Cardiomyopathies
Cytokines
Female
Genetic Predisposition to Disease
Hemodynamics
Humans
Inflammation
Myocarditis
Myocytes, Cardiac
Pregnancy
Pregnancy Complications, Cardiovascular
Prenatal Care
Prognosis
Prolactin
Risk Factors
Virus Diseases